ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies
文献类型：期刊论文
| 作者 | Ma, Yunzi; Liu, Xiaoqi; Huang, Jiawen; Lin, Huiran; Xiong, Lingjuan; Lao, Haiyan |
| 刊名 | JOURNAL OF CANCER
 |
| 出版日期 | 2018 |
| 文献子类 | 期刊论文 |
| 英文摘要 | Emerging epidemiological researches have been performed to assess the association of ESR1 PvuII (rs2234693 T> C) polymorphism with the risk of cancer, yet with conflicting conclusions. Therefore, this updated meta-analysis was performed to make a more accurate evaluation of such relationship. We adopted EMBASE, PubMed, CNKI, and WANFANG database to search relevant literature before January 2018. Odds ratios (ORs) and 95% confidence intervals (CIs) were employed to estimate the relationship strengths. In final, 80 studies (69 publications) involving 26428 cases and 43381 controls were enrolled. Our results failed to provide significant association between overall cancer risk and PvuII polymorphism under homozygous (TT vs. CC) and heterozygous (TT vs. CT) models. Statistically significant relationship was only observed for PvuII polymorphism in allele model T vs. C (OR= 0.95, 95% CI= 0.91-0.99). Stratification analysis by cancer type suggested that T genotype significantly decreased prostate cancer risk (TT vs. CC: OR= 0.79, 95% CI= 0.66-0.94; T vs. C: OR= 0.89, 95% CI= 0.82-0.98), Leiomyoma risk (T vs. C: OR= 0.82, 95% CI= 0.68-0.98), and HCC risk (TT vs. CC: OR= 0.45, 95% CI= 0.28-0.71; T vs. C: OR= 0.67, 95% CI= 0.47-0.95). Furthermore, significantly decreased risk was also found for Africans, population-based and hospital-based studies in the stratified analyses. These results suggest that ESR1 PvuII (rs2234693 T> C) polymorphism may only have little impact on cancer susceptibility. In the future, large-scale epidemical studies are warranted to verify these results. |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 源URL | [http://ir.siat.ac.cn:8080/handle/172644/14866]  |
| 专题 | 深圳先进技术研究院_其他 |
| 推荐引用方式 GB/T 7714 | Ma, Yunzi,Liu, Xiaoqi,Huang, Jiawen,et al. ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies[J]. JOURNAL OF CANCER,2018. |
| APA | Ma, Yunzi,Liu, Xiaoqi,Huang, Jiawen,Lin, Huiran,Xiong, Lingjuan,&Lao, Haiyan.(2018).ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies.JOURNAL OF CANCER. |
| MLA | Ma, Yunzi,et al."ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies".JOURNAL OF CANCER (2018). |
入库方式： OAI收割
来源：深圳先进技术研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。